Currently, the use of TPO agonists is approved for immune thrombocytopenia; nevertheless, several recent reports suggest their possible use in some IPD, such as the Wiskott–Aldrich syndrome, MYH9-related disorder, ANKRD26-related thrombocytopenia, and the GPIIb/IIIa- related thrombocytopenia [43]. The gene discussed is MYH9; the disease is Thrombocytopenia.